MDNA Life Sciences has entered into an exclusive license agreement with LabCorp® (LH) to develop and commercialize a non-invasive test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA “grey zone”.
Phi is our first US partner to distribute our proprietary liquid biopsy test for prostate cancer, the Mitomic Prostate Test (PMT™).
Specimen Testing is Now Commercially Available in the Clinical Laboratories of Helomics Corporation.
MDNA Life Sciences announces that it has entered into an exclusive license agreement with its first international commercial partner.